iRhythm Technologies (NSDQ:IRTC) said yesterday that it closed its underwritten public offering of common stock for gross proceeds exceeding $100 million. The San Fransisco-based company said it offered nearly 1.6 million shares at $73 per share, including the exercise in full of the underwriters’ option to purchase an additional 205,479 shares. iRhythm initially estimated net proceeds […]
iRhythm prices $100m offering
iRhythm Technologies (NSDQ:IRTC) yesterday priced a stock offering worth at least $100 million it plans to use in part to fund a co-development deal with Alphabet (NSDQ:GOOGL) life sciences unit Verily. The 1.37-million-share flotation includes a 30-day underwriters option on another 205,000 shares that would add $15 million if exercised in full. The offering is slated to close […]
iRhythm unveils $13m Verily afib deal, readies $100m offering
iRhythm Technologies (NSDQ:IRTC) said yesterday that it inked a deal worth nearly $13 million with Alphabet (NSDQ:GOOGL) life sciences unit Verily to develop AI-based screening, diagnosis and management technology for atrial fibrillation and said it’s readying a stock offering worth $100 million in part to back the collaboration. The deal to integrate Verily’s data analytics into […]
iRhythm rises on Q1 beats, raised sales outlook
iRhythm Technologies (NSDQ:IRTC) posted a classic beat-and-raise first quarter yesterday, topping the consensus forecasts on Wall Street and boosting its top-line outlook on the rest of the year. The San Francisco-based wearable heart monitor maker cut its losses by -27.9% to -$8.0 million, or -33¢ per share, on sales growth of 54.5% to $47.2 million […]
NIH director Collins touts AF detection capabilities of iRhythm’s Zio ECG patch
iRhythm Technologies‘ Zio ECG patch won praises from NIH Director Dr. Francis Collins this week for its ability to aid in the detection of atrial fibrillation. In an NIH Director blog post, Dr. Collins warned that while the dangers of atrial fibrillation are known, many individuals do not know they have atrial fibrillation and therefore […]
NinePoint Medical lifts Namati to the corner office | Personnel Moves – July 10, 2018
NinePoint Medical said earlier this month that it appointed Eman Namati as its new president and chief executive officer, succeeding Christopher von Jako who will remain on the company’s board of directors. Namati joined NinePoint Medical at its inception in 2010 as a technical co-founder, and operated as R&D VP for the past four years, […]
ACC ’18 Roundup: Abbott releases long-term HeartMate 3 data
Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure. Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session. More […]
iRhythm prices IPO above the range, raises $107m
iRhythm Technologies yesterday increased the scale of its initial public offering, pricing the flotation above its prior range at $17 per share and increasing the number of shares on offer. Earlier this month iRhythm said it planned to float 5.35 million shares priced between $13 and $15 apiece. Yesterday the San Francisco-based company added nearly 1.1 million shares, for a […]
iRhythm Technologies sets terms for $75m IPO
iRhythm Technologies last week set the terms on its forthcoming initial public offering, saying it plans to float 5.35 million shares priced between $13.00 and $15.00 apiece. At the midpoint, the IPO would fetch $74.9 million. San Francisco-based iRhythm has said it plans to use the proceeds to expand the commercial and clinical footprint of its Zio wearable cardiac […]
Wearable heart monitor maker iRhythm registers for $86m IPO
iRhythm Technologies last week registered for an initial public offering worth $86 million it plans to use to expand the commercial and clinical footprint of its Zio wearable cardiac monitor. San Francisco-based iRhythm won 510(k) clearance for the Zio device in 2009. It’s designed to be worn for 14 days to log heartbeat data; the company […]
Biolase CEO succession continues | Personnel Moves
Biolase (NSDQ:BIOL) said earlier this month that CEO Jeffery Nugent has resigned from both his position as CEO and the board of directors, effective July 12, to be replaced by Harold Flynn. Irvine, Calif.-based Biolase picked up Flynn, the former president of Zimmer Dental (NYSE:ZMH), in May to replace Nugent, who the company said had stepped in to […]
MassDevice Network
@MassDevice
LinkedIn
YouTube